CDE accepts the application for registration and listing of Apixaban tablets
On April 29, 2021, our company's generic drug marketing authorization application for Apixaban tablets received a drug supplement application approval notice from the National Medical Products Administration.
The acceptance of the application for Apixaban tablets is conducive to further enhancing the company's brand value, technological advantages, improving market competitiveness, and laying a strong foundation for subsequent generic drug consistency evaluation.
